We examined 122 patients with inflammatory bowel disease treated with salicylazosulfapyridine. Forty-two (34.5%) had adverse effects that led to discontinuation of therapy in 14 (11.5%). In 33 patients the effects appeared to be dose dependent. The plasma sulfapyridine levels in patients exhibiting gastrointestinal side effects were significantly higher than in patients with no adverse effects (41.0 ± 20.3 and 23.8 ± 14.8 μg/ml respectively, P <0.001). Plasma sulfapyridine levels were significantly higher in slow than in fast acetylators (31.5 ± 17.1 vs. 22.2 ± 17.1 μg/ml). Slow acetylators had three times as many side effects as fast acetylators; however this difference was not statistically significant.
|Number of pages||4|
|Journal||Israel Journal of Medical Sciences|
|State||Published - 1990|
- Acetylator phenotype